Kessler Topaz Meltzer & Check, LLP Encourages EyePoint, Inc. (NASDAQ: EYPT) Investors to Contact the Firm

EyePoint reported that its first pivotal Phase 3 LUGANO trial for DURAVYU (vorolanib intravitreal insert) did not meet the prespecified primary endpoint on the change in best-corrected visual acuity versus aflibercept in the full dataset for wet AMD. The stock fell over 66% following the topline clinical results. The firm is now investigating potential federal securities-law violations, reinforcing negative investor/regulatory sentiment around the trial outcome.

Analysis

This is now less a pure science miss than a credibility-and-funding event. After a 66% repricing, the incremental downside is more likely to come from model cuts, trial redesign costs, and a higher probability of dilutive capital raises than from the endpoint miss itself. That makes the stock vulnerable to a slow bleed over 1-3 months even if there is no new headline, because sell-side NPV models will compress both approval odds and terminal margin assumptions.

The clearest winners are the entrenched anti-VEGF incumbents, especially REGN/Bayer’s Eylea franchise and Roche/Genentech’s Vabysmo, because the market will lean harder toward proven injectable standards when long-acting delivery platforms stumble. Second-order, this raises the proof bar for every adjacent retinal drug/device company with a convenience narrative: investors will demand cleaner safety, durability, and manufacturing data before assigning premium multiples. There is no real fundamental read-through to AMD despite the ticker tag; this is an idiosyncratic biotech event.

The next catalysts are legal discovery, cash-runway scrutiny, and any attempt to reposition the pipeline over the next 30-90 days. The contrarian risk is that the market is treating this as platform failure, when a surviving subgroup, another indication, or a licensing transaction could create a sharp bear-market rally from oversold levels. What would invalidate a bearish follow-through is any financing completed with limited dilution or a credible new dataset that restores optionality beyond wet AMD.

Key Decisions for Investors

• Do not chase an outright EYPT short here; the easy money is likely gone after the gap. If borrow is cheap and liquidity allows, only lean short on 15-25% relief rallies over the next 2-4 weeks, with a tight stop if management announces a non-dilutive strategic transaction.
• Relative-value: long REGN vs. short EYPT for 1-3 months. Thesis is that capital will rotate back to the proven wet-AMD incumbents while EYPT faces dilution/legal overhang; keep sizing modest because EYPT is small-cap and squeeze-prone.
• Buy REGN on weakness for a 6-12 month hold if the market overprices spillover risk. The risk/reward is favorable if the failed platform narrative pushes investors toward incumbent durability and supports multiple stability.
• Set an alert on EYPT cash runway and any follow-on financing terms. If dilution exceeds roughly 15-20% or the company signals a broad pipeline reset, the bearish case extends into the next earnings cycle.